PITX2, paired like homeodomain 2, 5308

N. diseases: 248; N. variants: 27
Disease: Prostate carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE Therefore, a systematic review was performed to explore the relationship of PITX2 methylation with the BCR risk of prostate cancer. 30608394 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE PITX2 methylation discriminated between neoplastic and nonneoplastic tissue in patients with PCa (P < 0.001). 27939865 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE The PITX2 gene expression level in prostate cancer tissues was lower than that in benign tissues. 27173224 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Methylation was quantified by pyrosequencing assays for six genes (HSPB1, CCND2, TIG1, DPYS, PITX2, and MAL) with established biomarker value in prostate cancer. 27708246 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE To explore differential methylation of HAAO, HOXD3, LGALS3, PITX2, RASSF1 and TDRD1 as a molecular tool to predict biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa). 24938434 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Our findings, which significantly expand previous evidence that PITX2 is associated with risk of PCa biochemical recurrence, indicate that variation in PITX2 expression accompanies and may promote prostate tumor progression and metastasis. 24162257 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Recently, a diagnostic microarray for prostate cancer prognosis based on PITX2 methylation has been developed and validated. 23266319 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE Additionally, expression and methylation changes of PITX2 were investigated in prostate carcinoma cell lines. 21803613 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. 22495974 2012
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE GSTP1, APC, RARβ2 and PITX2 methylation occur frequently in prostate cancer, making these markers sensitive tools for the detection of neoplastic lesions in the prostate. 21116117 2010
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE DNA methylation of PITX2 has been established in several studies as a prognostic biomarker for breast and prostate cancer. 20304943 2010
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features. 20478579 2010
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 PosttranslationalModification disease BEFREE DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. 19233404 2009